Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Melanoma (cutaneous) (NRAS m) & Drugs/Treatments

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

MEK-inhibition has shown some albeit low activity
Awada & Neyns 2022 Current Opinion in Oncology 34(2): 115-122

MEK-inhibitors combined with novel RAF dimer inhibitors, such as belvarafenib, or with CDK4/6 inhibitors have promising activity in Melanoma (cutaneous) (NRAS m) in early-phase trials
Awada & Neyns 2022 Current Opinion in Oncology 34(2): 115-122

…

References (Sources)

Correlation of NRAS Mutations With Clinical Response to High-dose lL-2 in Patients With Advanced Melanoma
Joseph et al., 2012
Long-Term Response to Intermittent Binimetinib in Patients with NRAS-Mutant Melanoma
Matter et al. 2020
Melanoma with genetic alterations beyond the BRAF V600 management and new insights
Awada & Neyns 2022 Current Opinion in Oncology 34(2): 115-122
Review
Targeted therapies in melanoma beyond BRAF targeting NRAS mutated and KIT mutated melanoma
Delyon et al. 2020 Current Opinion in Oncology. 32(2): 79-84

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!

Melanoma (cutaneous) (NRAS m) & Drugs/Treatments

Welcome to meRfi Microbiome!

Navigation

Contents

References (Sources)

AI Chat